Announcement • Apr 08
InnoCan Pharma Corporation announced that it has received $0.2 million in funding On April 6, 2026,InnoCan Pharma Corporation closed the transaction. The company has raised $200,000 in the transaction. Announcement • Apr 02
InnoCan Pharma Corporation announced that it expects to receive $0.2 million in funding InnoCan Pharma Corporation announced that will receive gross proceeds of $200,000 in a round of funding on March 31, 2026. The transaction includes participation from new lender Tamar Innovest Limited. The company will issue non convertible debt in the transaction. The notes bear a fixed interest rate of 10% per annum and will be issued at par. The company will pay the accrued interest on a yearly period. The notes will will mature at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The transaction is expected close on April 1, 2026. Announcement • Mar 17
InnoCan Pharma Corporation announced that it has received $0.45 million in funding On March 16, 2026, InnoCan Pharma Corporation, closed the transaction. The company has received $450,000 in funding. Announcement • Mar 12
InnoCan Pharma Corporation announced that it expects to receive $0.45 million in funding InnoCan Pharma Corporation announced that will receive gross proceeds of $450,000 in a round of funding on March 11, 2026. The transaction includes participation from new lender Tamar Innovest Limited. The notes bear a fixed interest rate of 10% per annum and will be issued at par. The company will pay the accrued interest on a yearly period. The company issues non convertible debt in the transaction. The company will issue pursuant to its registration statement on F-1 filed with the U.S. securities and exchange commission. The transaction is expected close on March 12, 2026. Announcement • Aug 25
Innocan Pharma Corporation to Showcase a Poster Outlining Key Data on LPT-CBD Pharmacokinetics and Efficacy Along with the Recently Published Narrative Review Innocan Pharma Corporation announced that during the PAINWeek conference 2025, it will showcase a poster outlining key data on LPT-CBD pharmacokinetics and efficacy along with the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI:). PAINWeek is the premier US national conference on pain management, taking place this year in Las Vegas, Nevada, from September 2-5, 2025. The poster will be showcased during the scientific poster reception on September 4 (Poster #29), presented by Joseph V. Pergolizzi, Jr., MD, MBA, NEMA Research, a key member of Innocan's advisory board. PAINWeek is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by preclinical animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability-offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. Unlike over-the-counter CBD oils and supplements, Innocan's LPT-CBD is being developed as a pharmaceutical-grade, controlled-release injectable designed to deliver consistent therapeutic levels of CBD. The endocannabinoid system is a validated target in pain modulation, and Innocan's long-acting synthetic CBD platform may represent a breakthrough approach to harnessing this pathway. With opioid dependency remaining a global health crisis, LPT-CBD have the potential to emerge as a safe, effective non-opioid therapy for chronic pain management. LPT-CBD will be presented at the PAINWeek conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. Announcement • Jun 21
Innocan Pharma Corporation Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference Innocan Pharma Corporation announced that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability-offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of non-opioid chronic pain management solutions. Announcement • May 09
InnoCan Pharma Corporation, Annual General Meeting, Jun 26, 2025 InnoCan Pharma Corporation, Annual General Meeting, Jun 26, 2025. Announcement • May 07
Innocan Pharma Corporation First Granted Patent in Mexico for Its Topical Pain Relief Innocan Pharma Corporation announced that the Mexican patent office has issued a notice of allowance for the Company's patent application covering its proprietary topical pain-relief technology. This patent covers a formulation comprising the unique blending of cannabidiol with minerals to deliver fast-acting, targeted pain relief. Clinical studies have demonstrated noticeable pain reduction within 20 minutes of application. The approval of this patent represents a major milestone in Innocan's mission to advance next-generation topical therapeutic solutions. The Mexican allowance adds to previously granted counterpart patents in the United States, Russia, and Ukraine, and complements a growing portfolio of pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets. Innocan Pharma intends to continue expanding its intellectual property portfolio in other key territories worldwide, reinforcing its leadership in cannabidiol-based wellness innovation. Announcement • Apr 16
InnoCan Pharma Corporation announced that it has received CAD 0.214839 million in funding On April 15, 2025, InnoCan Pharma Corporation closed the transaction. The company issued 1,193,551 units at an issue price of CAD 0.18 per unit for gross proceeds of CAD 214,839.18. Announcement • Mar 08
InnoCan Pharma Corporation announced that it has received $1 million in funding On March 7, 2025, InnoCan Pharma Corporation closed the transaction. Announcement • Feb 28
InnoCan Pharma Corporation announced that it expects to receive $1 million in funding InnoCan Pharma Corporation announced a private placement to issue one secured convertible debenture and 5,555,555 common share purchase warrants for gross proceeds of $1,000,000 on February 27, 2025. The transaction will include participation from returning investor Tamar Innovest Ltd. The Debenture matures two years from the date of issuance, will bear interest at the rate of 10% per annum and is convertible into common shares of prior to the Maturity Date at a price of $0.21 per share Each Warrant is exercisable into one Common Share at a price of CAD$0.26 ($0.18141) for a period of four years from the date of issuance. The Offering is expected to close on or around March 6, 2025. The securities issued to Canadian subscribers in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. Announcement • Feb 11
Innocan Pharma Corporation Announces Successful Outcome from the Compassionative Treatment with Its Innovative Liposomal Cbd Injection (Lpt-Cbd) Innocan Pharma Corporation announced the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD injection (LPT-CBD). Innocan's innovative therapy provided quick and sustained pain relief, significantly improving mobility in an elderly female donkey suffering from osteoarthritis. Ariel, a 35-year-old elderly female donkey residing at a rescue farm, had endured years of carrying excessive weight, leading to debilitating osteoarthritis across multiple joints. The chronic pain severely limited her mobility, affecting her overall well-being. As an act of compassionate therapy, Ariel was administered a single LPT-CBD injection. Positive effects were observed, and Ariel mobility was improved for several weeks. Due to the remarkable success of the treatment, she was given a second LPT-CBD dose, which demonstrated continued improvement in her condition. LPT-CBD is a proprietary innovative injectable liposomal formulation designed for the sustained release of synthetic CBD, targeting the treatment of chronic pain in both human and veterinary patients. Announcement • Jan 02
InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding On December 31, 2024 InnoCan Pharma Corporation closed the transaction and issued 3,177,223 Units at a price of CAD 0.20 per Unit for aggregate gross proceeds of CAD 635,444.60. The Company paid an arm's length finder a cash fee of CAD 13,500 and issued to the finder 67,500 warrants attributable to investors introduced to the Company by the finder within 3 months following such introduction. Each Finder Warrant entitles the Finder to purchase one Common Share at an exercise price of CAD 0.28 for a period of four (4) years from the date of issuance. Announcement • Dec 20
InnoCan Pharma Corporation announced that it expects to receive CAD 0.7 million in funding Innocan Pharma Corporation announced a non brokered private placement of up to 3,500,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of CAD 700,000 on December 19, 2024. Each Unit will be comprised of one common share and one common share purchase warrant. ach Warrant will entitle the holder thereof to purchase one Common Share at a price of CAD 0.28 for a period of four years from the date of issuance. The securities issued to Canadian subscribers in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws Announcement • Oct 12
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs Innocan Pharma Corporation announced promising results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. LPT-CBD, a monthly injectable treatment, has the potential to have superior bioavailability by avoiding first-pass liver metabolism. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased, clearly noticeable well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years respectively after their owners reported significant improvement in quality of life when receiving the treatment in addition to conventional treatments. Previous pilot studies by Innocan have shown similarly encouraging outcomes. Announcement • Aug 30
InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding On August 29, 2024, InnoCan Pharma Corporation closed the transaction. The company issued 5,025,725 units of the Company at a price of CAD 0.22 per Unit for gross proceeds up to CAD 1,105,659.50 Announcement • Aug 23
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of up to 4,000,000 units of the Company at a price of CAD 0.22 per Unit for gross proceeds up to CAD 880,000 on August 22, 2024.The Offering is expected to close on or around August 29, 2024. Each Unit will be comprised of one common share in the capital of the Company; and one common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at a price of CAD 0.32 for a period of four years from the date of issuance. Announcement • Jul 27
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center Innocan Pharma Corporation announced that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. Announcement • May 10
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey Innocan Pharma Corporation announced the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility. Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri's condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her. As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed. Announcement • Mar 15
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding On March 14, 2024, InnoCan Pharma Corporation closed the transaction. The company has now issued 7,952,840 units at a price of CAD 0.25 per for the gross proceeds of CAD 1,988,210. Announcement • Mar 09
InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024 InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024. Agenda: Annual General Special Meeting. Announcement • Mar 06
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.25 per unit for gross proceeds up to CAD 3,000,000 on March 5, 2024. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.32 for a period of four years from the date of issuance. The offering is expected to close on or around March 13, 2024. The securities issued to Canadian subscribers in connection with the offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. Announcement • Oct 21
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding On October 20, 2023, InnoCan Pharma Corporation closed the transaction. The company issued 4,005,408 units at a price of CAD 0.3 per unit for the gross proceeds of CAD 1,201,622.4? in its final tranche. In total, the company issued an aggregate of 5,425,608 units under the offering for aggregate gross proceeds of CAD 1,627,682.40. The company also paid the Agent a corporate finance advisory fee consisting of 122,500 Units, CAD 27,700 in cash and 92,330 Broker Warrants. Announcement • Sep 22
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding InnoCan Pharma Corporation announced that it has entered into an agreement with Research Capital Corp. as the sole agent and sole bookrunner on a best efforts agency basis of up to 10,000,000 units of the company at a price of CAD 0.3 per unit for the aggregate gross proceeds of CAD 3 million on September 21, 2023. Each unit shall comprise one common share of the company and one common share purchase warrant of the company. Each warrant shall entitle the holder thereof to purchase one common share at an exercise price of CAD 0.36 for a period of 36 months from closing. The company will grant the agent an option to increase the size of the offering by up to 15% of the number of units by giving written notice of the exercise of the agent's option, or a part thereof, to the company at any time up to 48 hours prior to closing of the offering. The transaction is expected to close on October 10, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the Canadian Securities Exchange. The company has agreed to pay the agent a cash commission equal to 8% of the gross proceeds. The company will also pay the agent a corporate finance fee based on the aggregate gross proceeds of the offering, which will be satisfied by the issuance of units at the same offering price and on the same terms as those issued under the offering. Announcement • Sep 16
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board InnoCan Pharma Corporation announced the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications. Dr. Pergolizzi has extensive academic, clinical, and business achievements related to his lifelong interest in advancing medical science and the practice of modern global healthcare. He has gained a strong reputation as an experienced, results-oriented C-level leader with a particular focus on new companies. He has held various C-level positions in private and public companies. He can leverage his significant medical expertise, regulatory experience, and business skills to build a strong track record of success in many fields in the healthcare industry. Dr. Pergolizzi is a Senior Partner at Naples Anesthesia and Pain Associates and serves as the Chief Operating Officer at NEMA Research Inc. He is a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a Consultant to the National Pain Foundation Board of Directors. Dr. Pergolizzi is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He formerly served as a part-time adjunct assistant professor in the Department of Medicine at the Johns Hopkins University School of Medicine. Dr. Pergolizzi has authored over 400 peer-reviewed articles and has been involved in groundbreaking research on topics such as opioid-induced constipation, cardiotoxicity due to cocaine, and the effects of illicitly manufactured fentanyl. His research has been funded by the NIDA/NIH, and he has received numerous accolades, including the Patients Choice Award, Compassionate Doctor Recognition Award, and the Leading Physicians of the World by the IACHP. Announcement • Aug 09
InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding On August 8, 2023, InnoCan Pharma Corporation closed the transaction. Announcement • Aug 05
InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of 8,409,735 units at a price of CAD 0.23 per unit for a gross proceeds of CAD 1,934,239.05 on August 4, 2023. Each unit comprises of one common share, one and half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.29 for a period of three years from the date of issuance. Each class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.40 for a period of five years from the date of issuance. The security issued in the transaction are subject to hold period of four month. Announcement • Jul 26
InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding InnoCan Pharma Corporation announced that it has entered into a non-brokered private placement of 17,220,000 units at a price of CAD 0.23 per unit for gross proceeds of CAD 3,960,600 on July 25, 2023. Each unit consists of one common share and one half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each Class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.29 for a period of three years from the date of issuance. Each Class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.40 for a period of five years from the date of issuance. The securities issued in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. The transaction is expected to closing on July 20, 2023. Announcement • Jun 15
Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology InnoCan Pharma Corporation has announced the filing of its most recent patent application to the United States Patent and Trademark Office (USPTO). This move is in line with the Company's ongoing strategy to expand the breadth of its distinctive combined Cannabis and Magnesium topical pain-relief technology. This latest continuation patent application encapsulates additional aspects of the Company's combined Magnesium and Cannabis-based solution, explicitly crafted for pain and itching alleviation. The patent application reflects the broad spectrum of Cannabinoids and variable dosage, underlining the promising potential of this novel technology. Innocan is committed to broadening its cannabis-based intellectual property portfolio further and intends to continue filing additional patent applications with the USPTO as well as other global patent offices. This innovative company continues to position itself at the forefront of novel cannabis-based therapeutic solutions. Announcement • May 09
InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial Innocan Pharma Corporation announced the successful treatment of Billy, a 4-year-old neutered male goat, with a liposomal-CBD injection in a pre-clinical trial. The innovative therapy provided much-needed relief to the animal, born with neurological deficits and scoliosis, resulting in hind-limb paralysis and fore-limb deformity. Scientific research indicates that the success of a pre-clinical trial on large mammals (such as goats) generally infers increased bio-feasibility in similar rates amongst humans. Billy was adapted to move around with a wheelchair, but as his size and weight increased, his scoliosis worsened, and his activity decreased substantially. Despite being administered non-steroidal anti-inflammatory drugs, the goat's pain persisted, and he was unable to move on his wheelchair. As an act of compassion therapy, Billy was administered a lipos anomalies-CBD injection on top of the drugs he was already taking. The results were almost immediate, with the goat becoming active and playing as he used to do over a year ago. The improvement in Billy's activity lasted for almost 4 weeks. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. Announcement • Feb 17
InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding InnoCan Pharma Corporation announced that it has entered into a non-brokered private placement of 1,982,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 495,500 on February 16, 2023. Each unit consists of one common share and one half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each Class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.31 for a period of two years from the date of issuance. Each Class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.44 for a period of three years from the date of issuance. All common shares and warrants issued pursuant to the offering will be subject to a four-month statutory hold period commencing from the closing date under applicable securities laws.